Improvement in multiple dimensions of fatigue in patients with fibromyalgia treated with duloxetine: secondary analysis of a randomized, placebo-controlled trial

Table 3 Multidimensional Fatigue Inventory ratings in patients who were escalated to a higher duloxetine dose

Multidimensional Fatigue Inventory	Duloxetine 90 mg (n= 59)^a		Duloxetine 120 mg (n= 63)^b
	Rating before escalation	Endpoint	Rating before escalation	Endpoint
	Mean (SD)	Mean change (SD)	Mean (SD)	Mean change (SD)
General Fatigue	15.3 (3.4)	-0.7 (3.6)	16.0 (3.1)	-0.2 (3.0)
Mental Fatigue	12.1 (4.6)	-0.9 (3.0)	11.7 (4.0)	0.1 (3.3)
Physical Fatigue	14.6 (3.9)	-1.3 (3.7)	14.2 (3.6)	0.1 (2.6)
Reduced Activity	12.8 (4.3)	-1.0 (3.5)	12.8 (4.2)	0.2 (3.1)
Reduced Motivation	11.4 (3.9)	-1.1 (3.3)	11.5 (3.5)	-0.1 (3.1)

^aPatients who responded to duloxetine 90 mg QD. ^bPatients who did not respond to the 90 mg dose and were escalated to 120 mg. A last-observation-carried-forward analysis was conducted at acute-phase endpoint (week 12). SD, standard deviation.

ISSN: 1478-6362